| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5427798 | GLAXOSMITHKLINE | Controlled sustained release tablets containing bupropion |
Aug, 2013
(10 years ago) | |
| US5731000 | GLAXOSMITHKLINE | Stabilized pharmaceutical composition containing bupropion |
Aug, 2013
(10 years ago) | |
| US5763493 | GLAXOSMITHKLINE | Stabilized pharmaceutical |
Aug, 2013
(10 years ago) | |
| US5358970 | GLAXOSMITHKLINE | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
Aug, 2013
(10 years ago) | |
Zyban is owned by Glaxosmithkline.
Zyban contains Bupropion Hydrochloride.
Zyban has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Zyban are:
- US5427798
- US5731000
- US5763493
- US5358970
Zyban was authorised for market use on 14 May, 1997.
Zyban is available in tablet, extended release;oral dosage forms.
The generics of Zyban are possible to be released after 12 August, 2013.
Drugs and Companies using BUPROPION HYDROCHLORIDE ingredient
Market Authorisation Date: 14 May, 1997
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of ZYBAN before it's drug patent expiration?
More Information on Dosage
ZYBAN family patents
